CONGENITAL HYPERINSULINISM TREATMENT MARKET ANALYSIS

Congenital Hyperinsulinism Treatment Market, by Disease Type (KATP-HI, GDH-HI, GK-HI, Other (SCHAD HI,HNF4A/HNF1A, etc.)), by Drug Type (Diazoxide, Octreotide, Glucagon, Nifedipine, Other (Sirolimus, Chlorothiazide, etc.), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5329
Pages :190
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Congenital Hyperinsulinism Treatment Market: Restraint

The major factors that hinder growth of the global congenital hyperinsulinism treatment market include high cost of total annual treatment of first line of therapy. For instance, according to the data published by BioMedCentral Journal, an Orphanet Journal of rare diseases, in July 2018, the total annual cost of first line therapy is substantially high for congenital hyperinsulinism because of lack of response that is the cost of illness of CHI patients was US$ 13,144,870 annually and average cost per patient was US$ 2,083.19. Cost distribution was skewed among CHI patients, with 5.9% of patients (95 patients in their first year of life) contributing to 61.8% (U.S$ 2105491) of total costs which is high as compared to first line therapies.

Restraints & Challenges:

High treatment cost for congenital hyperinsulinism